CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

If you have multiple myeloma that has relapsed after remission or is resistant to treatment, you may be eligible for chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy treats a number of blood cancers, offering new hope to adult patients with relapsed or refractory multiple myeloma, leukemia and non-Hodgkin diffuse large B-cell lymphoma.

Eighty percent of blood cancer patients treated with CAR T-cell therapy at UH Seidman Cancer Center have experienced either complete or partial remission after treatment.

How CAR T-Cell Therapy Works

CAR T-cell therapy works by extracting a type of white blood cell (T-cells) from a patient’s blood and modifying them in a lab to recognize and destroy cancer cells. The modified T-cells are injected into the patient’s body to seek out and kill cancer cells. This treatment is used after standard treatments, including chemotherapy, radiation and stem cell transplant, haven’t been effective.

Understanding Immunotherapy in Cancer Treatment

Immunotherapy is a cancer treatment that uses the body’s own immune system to fight cancer.

Generating Cellular Therapies On-site at UH Seidman Cancer Center

Immunotherapy is the next frontier in cancer therapy. It uses the body’s own immune system to fight cancer. At University Hospitals Seidman Cancer Center, we are able to generate cellular therapies onsite, allowing us to get these cancer treatments to patients more quickly.